Company intelligence / Profile preview
Adimune
United Statesadimune.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Adimune’s ADI platform shows preclinical efficacy in models of skin grafting, psoriasis, type 1 diabetes, and alopecia areata. There is no clinical data published yet, but the company claims selective immune tolerance via apoptotic DNA technology and has signed early-stage co-development agreements with major pharmaceutical partners.
- Therapeutic areas
- DermatologyImmunologyEndocrinology
- Modalities
- DNA therapyPlasmid DNA-based therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Early-stage co-development agreements with undisclosed major pharmaceutical companies
Beyond the preview
Go deeper on Adimune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adimune.